Development of aquantitative ELISA detection method for Varicella Zoster Virus VZV antigen

Transcript

1 doi /j. issn X ELISA R392. A X VZV ELISA VZV VZV 5F6C8 8H5D VZV ELISA VZV ELISA 0. 4 μg ~ 3 μg /ml R 2 = μg /ml CV < 5% 87. 5% ~. 6% 37 6 > 80% VZV VZV ELISA VZV - ELISA Development of aquantitative ELISA detection method for Varicella Zoster Virus VZV antigen ZHOU Qin JIA Ji-Zong LIU Jian CHEN Li-Hong YANG Lian-Wei ZENG Li-Wen HAN Jin-Le YE Xiang- Zhong LI Yi-Min XIA Huan-Zhang. College of Life Science and Biopharmaceutics Shenyang Pharmaceutical University Shenyang 006 China Abstract Objective To develop a quantitative enzyme linked immunosorbent assay Q-ELISA to determine the concentration of Varicella Zoster Virus VZV antigen. This method was used to determine VZV antigen content at each stage of VZV inactived vaccine developing and manufacturing process. Methods A double antibody sandwich Q-ELISA was developed to determine concentration of VZV antigen which was based on the the high-affinity neutralizing monoclonal antibodies 5F6C8 as capture antibodies and 8H5D as HRP-labeled antibody. The performance of reagent were evaluated. Results The Q-ELISA for VZV antigen content was successfully developed. The reagent had good performance. The quantitation scope was 0. 4 μg ~ 3 μg /ml The coefficient correlation was the limit of detection was 0. 4 μg /ml the was between 87. 5% and. 6%. The stability was up to 80% after reagent was heated for 6 days at 37. The variation coefficient was lower than 5% and the reagent was no reaction with other sample except VZV antigen. Conclusion The Q-ELISA for VZV antigen was developed with good specificity accuracy and stability. The method can be used to determine VZV antigen content during development and production of VZV inactived vaccine. Key words Varicella Zoster Virus VZV Antigen Double antibody sandwich ELISA - Varicella Zoster Virus VZV α- % 5 Varicella Herpes Zoster 0% ~ 50% 5% zhouqinhubei@ 26. com yxzh_hb@ 63. com 3 50% 60

2 - ELISA ELISA HRP 4 VZV 7 VZV VZV. 6. VZV VZV 2 μg /ml 6 μg /ml VZV 3 μg /ml 3 VZV 3... VZV 5F6C8 VZV 8H5D μg /ml 3 μg /ml 3 VZV VZV CMV Ⅰ/Ⅱ HSVⅠ/Ⅱ HAV A 6 CA EV7.. 3 BSA μg /ml HRP Sigma BCA OD Thermo -HRP. 2 VZV VZVgp 5 BALB /c VZV-gp Sp2 /0 PEG VZV OD ELISA Q Sepharose High Performance Protein A HAV VZV CMV HSVⅠ /Ⅱ CA6 mab μg /ml VZV MRC-5. 3 VZV-gp MEM VZV Western blot VZV- Ag. 4 ELISA 6 AI = 2 A + 2 / 2 A + A2-00% 2 A + 2 OD 450 nm A 2. OD 450 nm A2 OD 450 nm Western blot VZV AI > 50% 5F6C8 AI 8H5D HRP

3 ELISA Tab. The characteristics of two VZV antibodies 2 5F6C8 VZV-gp 8H5D VZV-gp 200 μl / μl / μl / TMB 00 μl / mol /L H 2 SO /630 3 Tab. 3 Verification of accuracy and precision of Q-ELISA A A % ~. 6% < 5% 3 Neutralizing Antibody McAb name Purpose Epitope Ab type antibody titer titer 8H5D HRP sign K Linear IgG 2a 2. 3 ELISA 5F6C8 coating K Linear IgG VZV ELISA 50 mmol /L ph μg /ml μl / 4 2 Tab. 2 ELISA The result of superposable ELISA test Mabs 5F6C8 8H5D 5F6C8 8H5D % VZV antigen concentration μg /ml Average μg /ml Recovery ratio % CV % ± ± ± Fig. VZV Western blot Western blot of antibodies against VZV Note A. SDS-PAGE of samples B. Western blot of 5F6C8 C. Western blot of 8H5D. Marker 2. VZV-gp 3. NBS 4. Vaccine protectant 5. Plasbumin 6. MRC-5 7. VZV. 2 Fig. 2 Plaque assay of monoclonal antibody against VZV Note A. 5F6C8 plaque assay B. 8H5D plaque assay C. Negative hybridization D. Positive hybridization.

4 - ELISA VZV-gp μg /ml R = μg ~ 3 μg /ml R 2 = μg VZV > 80% % PHN A 450 / μg /ml Cutoff VZV Fig. 3 Standard curve of internal reference of VZV antigen Rebecca 2 Ste- 3 4 ven Tab. 4 Verification of thermostability of Q-ELISA 37 d Coating Enzyme Sample Entirety 3 00% 85% 96% 83% 6 00% 86% 93% 82% PHN HIV Atsuko IFN-γ TNF-α VZV CD4 T VZV HIV Anthony 4 T IFN-γ VZV VZV T VZV VZV VZV VZV 4 VZV-antigen VZV Ag Fig. 4 Correlation analysis of VZV-antigen concentration and Herpes Zoster vaccine titer relationship 552

5 Ochi T Fujiwara H Okamoto S et al. Novel adoptive T-cell immunotherapy using a WT-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety J. Blood Provasi E Genovese P Lombardo A et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer J. Nat Med Nicholson E Ghorashian S Stauss H. Improving TCR gene therapy for treatment of haematological malignancies J. Adv Hematol Thomas S Stauss H J Morris E C. Molecular immunology lessons from therapeutic T-cell receptor gene transfer J. Immunology Kronig H Hofer K Conrad H et al. Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO- have potent anti-tumor activity J. Int J Cancer Zhao Y Bennett A D Zheng Z et al. High-affinity TCRs generated by phage display provide CD4 + T cells with the ability to recognize and kill tumor cell lines J. J Immunol Kuball J Hauptrock B Malina V et al. Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain J. J Exp Med Johnson L A Morgan R A Dudley M E et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen J. Blood Parkhurst M R Yang J C Langan R C et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis J. Mol Ther Robbins PF Morgan R A Dudley ME et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO- J. J Clin Oncol Chinnasamy N Wargo J A Riley JP et al. A TCR targeting the HLA-A* 020-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer J. J Immunol VZV Ag 8 M herpes zoster and postherpetic neuralgia in older adults Med years J 5 ANN M. ARVIN. Varicella-zoster virus J. J Clin Microbiol Rev Gnann J W Jr Whitley R J. Herpes zoster J. N Engl J Med David W W Judith B. Herpes zoster J. J Clin Rev Andrea D John A. G Saul K et al. Vaccinations for adult solid-organ transplant recipients current recommendations and protocols J. J Clin Microbiol Rev Yusuke H Tokuhiro C Takuma I et al. Preparation of mouse monoclonal antibody for RBCC and its clinical application J. Plos One e et al. N J et al. A 6 ELISA J Oxman M N Levin M J Johnson GR et al. A Vaccine to prevent J. N Engl J 0 Robert A Anne F Stéphane T et al. Immunogenicity and safety of ZOSTAVAX approaching expiry potency in individuals aged 50. Hum Vaccin Atsuko H Hideomi A Mary R et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants J. N Engl J Med Rebecca L R Sonia N Leigh Z et al. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine J. J Infect Dis Steven J S Barbara V S Frederick G H. Serologic response and reactogenicity to booster immunization of healthy seropositive adults with live or inactivated varicella vaccine J. Anti Res Anthony R H Kim B Myron J L. Immune response to secondary immunization with live or inactivated VZV vaccine in elderly adults J. Vir Immun